The Lilly Foundation has committed US $30 million to The Lilly MDR-TB Partnership over the next five years (2012 to 2016). This funding will be used to advance the partnership's efforts in two key areas of focus: training for health care providers and improving supply and access to safe, effective, and quality-assured second-line medicines. Watch our video news release to see how The Lilly MDR-TB Partership is making a difference in the lives of people and communities most affected by multidrug-resistant tuberculosis. Then learn more in our company press release.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.